Jumpstart Health Investors

VentureBlick is a super incubator for medtech. We provide a fully customisable one-stop solution to develop, test, and market healthcare innovations. Leveraging our global advisor network, the deep industry roots of our founding team, and extensive partnership, VentureBlick streamlines the startup journey, from ideation and testing to venture building and market success. ​ Our global VB Advisory Network has more than 1,200 medical and industry advisors, from more than 50 countries covering over 30 specialty areas. They play important roles in different capacities and different stages of startup development, to help accelerate innovations. ​ VentureBlick was founded in 2022 by senior healthcare executive, Chris Lee, with the vision of helping healthcare startups thrive. ​ We are headquartered in Singapore with presences in Australia, China, Germany, India, Korea, and USA.

HealthCap is a European venture capital firm investing exclusively and globally in life sciences. The investment strategy focuses on diseases with high unmet medical needs and breakthrough therapies that have the potential to be transformative and change medical practice, and the lives of patients suffering these conditions. Having raised more than EUR 1.2 billion since 1996, HealthCap has backed and built more than 125 companies, taken more than 45 companies public and done numerous trade sales. Over the years, HealthCap companies have developed more than 25 pharmaceutical products to market approval, many of which are breakthrough therapies helping patients with life-threatening diseases. In addition, HealthCap companies have brought more than 50 innovative medical device products to market. These products have generated significant value to many stakeholders, including patients, physicians and society, and as a result also to HealthCap investors.

We focus on investment opportunities within the healthcare and life science markets where we can identify value early. At the core of our investment philosophy is a committed and collaborative approach to working with management teams and syndicate partners to build successful companies. We work actively with founders, providing guidance, support and access to our network. We strongly believe that no two investments are the same and support the most suitable business model for each individual venture, working with management teams to formulate strategies to achieve financial independence. We are comfortable financing companies by ourselves and, if appropriate, working closely with the founders to help build a syndicate of co-investors who bring complementary relationships and share our vision. We have a 14-year history of continuous dedication to the fast growing MedTech sector and a history of backing successful entrepreneurs transforming healthcare through MedTech innovation. Investment Strategy Focus: Within the broader healthcare market, we focus our investments on medical technologies including medical devices, diagnostics, drug delivery, and digital health. We back both first-time and experienced founders, who value our participation as well our capital. Stage: We are typically the first institutional investor and support companies through early product and clinical development and often through the regulatory process. We make our first investment at the seed through series B stage, based on when the risk of translation from pre-clinical to clinical is at its lowest. We are life cycle investors and continue to support our portfolio companies through to exit. Capital Efficiency: We invest in companies that are able to demonstrate early and meaningful clinical value with minimum capital invested and preserve the most appropriate exit opportunity. Therapeutic Indications: While we are agnostic to therapeutic indication, we invest in companies developing products that address large, global markets and where there is significant unmet clinical need. We particularly like therapeutic devices that significantly improve patient outcomes and diagnostics that fundamentally change the course of therapeutic intervention.

At Boomerang Ventures, we believe better patient care begins with identifying and solving the biggest challenges in healthcare. Boomerang Ventures partners with founders, investors, and institutions that are leveraging new technologies to disrupt healthcare for the better. With our combination studio and venture fund, we provide the collaborative direction, deep industry expertise, and continuum of support founders need to take their innovations from ideation to market. Seamless Approach to Innovation. Our combination studio and fund work together to bring transformative healthcare ideas to life. Connected Health Technology Focus. We build and invest in connected health companies that are shaping a better future for healthcare. Collaborative Investors. We value our partners’ perspectives and work collaboratively to realize our shared vision. CONNECTED HEALTH TECHNOLOGY. Between rising costs, aging populations, staffing shortages, and increasing chronic disease, our healthcare system is struggling to provide the quality of care that patients need and deserve. Our experienced team has been in the Midwest healthcare and life science ecosystem for decades and knows what goes into launching, growing, and scaling successful healthcare companies. With our fund and studio, we are building health tech companies to improve the quality, accessibility, delivery, efficiency, and overall experience of patient care. We make investments in high-potential Midwest companies where our team can drive outsized impact. We focus on key healthcare sectors experiencing accelerated digital and care model transformation, including machine learning, artificial intelligence, virtual care, remote patient management and more. Together, these interconnected areas are paving the way for a brighter future in healthcare. OUR CORE VALUES. Driving the future of healthcare technology from the Midwest, for the world. Intentional Innovation: We push ourselves to think beyond the obvious. We leverage flexible creativity and structured methodology to innovate a future we all deserve. Committed To Collaboration: Our best work happens collaboratively as a team. We listen well and communicate constructively with each other and our partners to create lasting impact. Results that Matter: We focus on positively impacting patient experiences and outcomes. We set high-performance goals and follow through to improve the health of our communities and beyond.

DaVita Venture Group is committed to building partnerships with health care innovators to help improve the lives of patients with kidney disease and related conditions. Together, we believe we can transform the future of patient care for the better. Our Strategy We aim to invest in, acquire, and co-develop products, solutions and businesses that improve care for patients with kidney disease and related conditions. PrioritiesCare Delivery Models: Advancements to expand access to care and improve clinical outcomes through adoption of tech-enabled services, home treatments and value-based care Life Sciences: Pharmaceuticals, medical devices and diagnostics that can improve clinical outcomes and patient experience while reducing costs Digital Health: Products and services that leverage technology, data and connectivity to improve care delivery

AGP is a fund management company spun out from EDBI, a state-owned fund in Singapore, with former senior employees as founders. The fund will continue to have close affiliation to EDBI providing unique opportunities for collaboration and investments. We are raising a dedicated healthcare fund (“AGP Healthcare Fund” or “AGPHC”) to build on our successes at EDBI and to capture new opportunities. Our partners have a credible reputation built on years of working together at EDBI and having strong domain expertise in healthcare, with extensive network and deep linkages to the Singapore, regional, and global biomedical and healthcare ecosystem. Our investment areas* include medtech & manufacturing, services & others, healthtech, and biotech & therapeutics. At AGP Healthcare Fund, we focus on investing in growth-stage companies (Series C to pre-IPO) (~75%) and venture-stage companies (Series A and B) (~25%). Our unique position in serving both SEA/Asia and global markets is driven by our belief that SEA is an emerging innovation hub with tremendous potential to build differentiated and valuable healthcare companies. We see opportunities for healthcare companies to capitalize on the Asian growth momentum by leveraging Singapore's position as a nexus between the East and the West. With our global insights and proven track record, we provide valuable guidance and advice to founders in expanding their businesses globally. Investment areasMedtech & Mfg, Services & Others: minimally invasive devices, medical equipment manufacturing & distribution, surgical robotics, diagnostics, healthcare services, new modalities CRDMOs, life science equipment & consumables, drug manufacturing & distribution Healthtech: remote patient monitoring, virtual care delivery, digital health platform, workflow automation, healthcare analytics, AI in healthcare imaging, digital therapeutics, chronic disease management Biotech & Therapeutics: cell & gene therapy, RNA therapeutics, AI drug discovery, targeted therapy & immunotherapy, gene editing tools & infrastructure, regenerative medicine & tissue engineering, and life science tools